

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Mota Ventures Corp.** (the “Issuer”).

Trading Symbol: **MOTA**

Number of Outstanding Listed Securities: **210,195,805**

Date: **July 7, 2020**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On June 1, 2020, the Issuer announced that it would offer (the “Offering”) up to 11,111,112 units (each, a “Unit”), at a price of \$0.45, by way of non-brokered private placement, for gross proceeds of up to \$5,000,000. Each Unit to consist of one common share of the Issuer, and one common share purchase warrant exercisable to acquire an additional common share at a price of \$0.90 per share for a period of twenty-four months. At this time, the Issuer has not completed the Offering.

On June 2, 2020, the Issuer completed a Cdn\$20,000,000 acquisition (the “Transaction”) of all of the outstanding share capital of Verrian Ontario Ltd. (“Verrian”). Verrian is an established and well advanced European psychedelic medicine company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

In consideration for the acquisition of all of the outstanding share capital of Verrian, the Issuer issued 54,347,826 common shares (the “Consideration Shares”) to the existing shareholders of Verrian at a deemed price of \$0.368 per Consideration Share. 50,543,478 of the Consideration Shares are subject to terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The Consideration Shares will be released from the pooling arrangement in tranches, of which ten-percent will be released after four months, fifteen percent after six months, and the balance in five equal tranches every six months thereafter.

In addition to the Consideration Shares, upon closing of the Transaction, the Issuer has arranged for repayment of \$150,000 of existing shareholder loans of Verrian, and will arrange for repayment of the balance of \$950,000 within sixty days of closing.

The Issuer is at arms-length from Verrian, and each of its shareholders. The Transaction does not constitute a fundamental change for the Issuer, nor has it resulted in a change of control of the Issuer, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. In connection with completion of the Transaction, the Issuer has paid a finders’ fee of 5,434,783 common shares to certain arms’-length parties who have assisted in facilitating the Transaction. The Issuer has also paid an administrative fee of 1,086,957 common shares of the Issuer to a consultant who assisted with the Transaction

On June 6, 2020, the Issuer announced a binding term sheet with Unified Funding LLC (“Unified”) that replaced the previous preliminary letter of intent entered into with Unified on May 21, 2020. The binding term sheet contemplates that the Issuer will acquire Unified in consideration for US\$45,000,000, which will be satisfied through the issuance of common shares of the Issuer (the “Mota Consideration Shares”). The Mota

Consideration Shares will be issuable at a deemed price (the “Transaction Price”) equivalent to the greater of: (i) the volume-weighted average closing price of the common shares of the Issuer on the Canadian Securities Exchange in the ten trading days prior to the entering into of a definitive agreement in respect of the acquisition, and (ii) Cdn\$0.40.

In addition to the Mota Consideration Shares, Unified will be entitled to receive a one-time bonus payment of US\$15,000,000 (the “Bonus Payment”) in the event the Issuer achieves gross revenue in excess of US\$15,000,000 from the Unified business in the twelve-month period following closing of the acquisition. The Bonus Payment will be payable in common shares of the Issuer (the “Bonus Shares”), at the Transaction Price.

The Mota Consideration Shares, and the Bonus Shares, will be subject to terms of a thirty-six month time-release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The shares will be released from the pooling arrangement in tranches, of which twenty percent will be released upon issuance, and the balance in six equal tranches every six months thereafter.

The proposed acquisition is not expected to constitute a fundamental change for the Issuer, nor is it expected to result in a change of control of the Issuer, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange.

In the June 10, 2020 press release, the Issuer announced that its subsidiary, Nature’s Exclusive, an eCommerce provider of CBD products to consumers in the United States, announced an all-time monthly revenue record achieved during May 2020. Revenue for the month of May totaled Cdn\$5,141,000, representing an increase of 110% compared to May 2019. Expenses totaled Cdn\$4,992,000 for the month, representing a gross profit of Cdn\$149,000 for May 2020.

On June 13, 2020, the Issuer announced the appointment of Roger C. Clinton, to the Advisory Board for its wholly owned subsidiary, Verrian GmbH. Clinton is active within the addiction treatment (and specifically opiate addiction) research sector, seeking to bring attention to the issue and enhance promising treatment options using psychedelics in conjunction with behavioral therapy through his global network.

On June 19, 2020, the Issuer announced the appointment of Prof. Dr. Markus Backmund MD, PhD, as Principal Investigator and Director of Clinical Research for its wholly owned subsidiary, Verrian GmbH. Prof. Dr. Backmund serves as Chair of the German Society of Addiction Medicine and is regarded as a pioneer in addiction medicine.

On June 23, 2020, the Issuer announced that Sweet Earth Holdings Corp. (“Sweet Earth”) will become the exclusive dog treat provider to the Issuer’s eCommerce direct consumer brand, Nature’s Exclusive.

2. Provide a general overview and discussion of the activities of management.

Management of the Issuer has been engaged in integrating its newly acquired company, Verrian, into its business, raising money, growing its online CBD businesses in the United States (Natures Exclusive CBD), launching and acquiring new products and expanding its European presence with its Sativida brand. Management of the Issuer was also in discussions with various companies that it has considered acquiring, including Unified.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer did not launch any new products, though it did sign a letter of intent with Sweet Earth to become the exclusive dog treat provider to the Issuer’s eCommerce direct consumer brand, Nature’s Exclusive.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned. **None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship. **The Issuer entered into a letter of intent with Sweet Earth for Sweet Earth to become the exclusive dog treat provider to the Issuer’s eCommerce direct consumer brand, Nature’s Exclusive. The Issuer also completed its Cdn\$20,000,000 acquisition of all of the outstanding share capital of Verrian—an established and well advanced European psychedelic medicine company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates. Additionally, the Issuer also engaged Elektrik Dojo to provide investor relations services and written and video interview coverage of news releases and other corporate developments. Both of these relationships are arm’s-length.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced. **Not Applicable.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship. **The Issuer completed a Cdn\$20,000,000 acquisition of all of the outstanding share capital of Verrian.**

Describe the acquisition of new customers or loss of customers. **New customers are consistently acquired through Nature's Exclusive's e-commerce platform.**

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks. **None.**
9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs. **The Issuer announced the appointment of Roger C. Clinton, to the Advisory Board for its wholly owned subsidiary, Verrian GmbH and the appointment of Prof. Dr. Markus Backmund MD, PhD, as Principal Investigator and Director of Clinical Research for Verrian GmbH.**
10. Report on any labour disputes and resolutions of those disputes if applicable. **None.**
11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings. **None.**
12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness. **Not Applicable.**
13. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common shares	54,347,826	The common shares were issued at \$0.368 to acquire Verrian. See Item 1 for further details	See Item 1 for further details.

(1) State aggregate proceeds and intended allocation of proceeds.

FORM 7 – MONTHLY PROGRESS REPORT

14. Provide details of any loans to or by Related Persons. **None.**
15. Provide details of any changes in directors, officers or committee members. **None.**
16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

In December 2019, the 2019 novel coronavirus ("COVID-19") surfaced in Wuhan, China. The World Health Organization declared a global emergency on January 30, 2020 with respect to the outbreak and then characterized it as a pandemic on March 11, 2020. The outbreak has spread throughout the United States, Europe and Canada, causing companies and various international jurisdictions to impose restrictions, such as quarantines, closures, cancellations and travel restrictions. While these effects are expected to be temporary, the duration of the business disruptions internationally and related financial impact cannot be reasonably estimated at this time. Such public health crises can result in volatility and disruptions in global supply chains, business operation and financial markets, as well as declining trade and market sentiment and reduced mobility of people, all of which could affect, interest rates, credit ratings, credit risk and inflation. The risks to the Issuer of such public health crises also include risks to employee health and safety and a slowdown or temporary suspension of operations in geographic locations impacted by an outbreak, labour shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). At this point, COVID-19 has not negatively impacted the business of the Issuer and has instead led to an increase in online sales of new products. Despite the initial positive impact, the extent to which COVID-19 may impact the Issuer is uncertain and it is possible that COVID-19 may have a material adverse effect on the Issuer's business and financial condition.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 7, 2020.

Szascha Lim
Name of Director or Senior Officer

/s/Szascha Lim
Signature

Chief Financial Officer
Official Capacity

<i>Issuer Details</i> Name of Issuer Mota Ventures Corp.	For Month End June 2020	Date of Report YY/MM/DD 20/07/07
Issuer Address Suite 800 – 1199 W Hastings Street,		
City/Province/Postal Code Vancouver BC V6E 3T5	Issuer Fax No. ()	Issuer Telephone No. +1.604.423.4733
Contact Name Joel Shacker	Contact Position President & Director	Contact Telephone No. +1.604.423.4733
Contact Email Address IR@motaventuresco.com	Web Site Address www.motaventuresco.com	

FORM 7 – MONTHLY PROGRESS REPORT